Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
NCT06692881
Recruiting
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. This study will evaluate function and satisfaction with oral ubrogepant in treating adult participants after multiple migraine attacks. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Approximately 167 participants will be enrolled in approximately 10-15 sites across Canada. Participants will receive ubrogepant as... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Calgary Headache Assessment and Management Program /ID# 271475, Calgary, Alberta +9 locations
Conditions: Migraine
Register for Updates
A Study to Evaluate Microneedle-based Collection of Dermal Interstitial Skin Fluid in Healthy Participants and Atopic Dermatitis Participants
NCT06934980
Recruiting
The purpose of this study is to evaluate microneedle-based collection of dermal interstitial skin fluid (dISF) in healthy participants and atopic dermatitis (AD) participants
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/09/2025
Locations: Innovaderm Research Inc., Montreal, Quebec
Conditions: Atopic Dermatitis, Healthy Volunteers
Register for Updates
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875
Recruiting
This is a Phase Ⅲ, randomized, open-label, Sponsor-blinded, 3-arm, global, multicenter study assessing the efficacy and safety of rilvegostomig in combination with fluoropyrimidine and T-DXd (Arm A) compared to trastuzumab, chemotherapy, and pembrolizumab (Arm B) in HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma participants whose tumors express PD L1 CPS ≥ 1. Rilvegostomig in combination with trastuzumab and chemotherapy will be evaluated in a separate arm (Arm C) to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Anchorage, Alaska +264 locations
Conditions: HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Register for Updates
How Digital Media Affects Kids' Healthcare Experiences and Outcomes
NCT07073027
Recruiting
The goal of this clinical trial is to learn whether different forms of media (2D, 360, or 360 in virtual reality) have different impacts on pre-procedural anxiety and post-procedural pain in children. The main questions it aims to answer are: Does one type (and richness) of media reduce pre-procedural anxiety and post-procedural pain more than another type of media? For example, will learning about an upcoming procedure by watching a 360 video in virtual reality reduce pre-procedural anxiety mo... Read More
Gender:
ALL
Ages:
Between 5 years and 23 years
Trial Updated:
07/09/2025
Locations: BC Children's Hospital, Vancouver, British Columbia
Conditions: Children, Adolescent, Anxiety, Pain, Education, Exposure, Virtual Reality
Register for Updates
Cannabidiol Medication Intervention Trial
NCT06014424
Recruiting
CALM-IT is a Randomized, double-blind, placebo-controlled cross-over clinical trial. Safety and efficacy of cannabidiol (CBD) capsules assessed for managing agitation in patients with AD and to identify novel biomarkers of agitation severity and treatment response.
Gender:
ALL
Ages:
55 years and above
Trial Updated:
07/09/2025
Locations: University of Calgary, Calgary, Alberta +4 locations
Conditions: Alzheimer Disease
Register for Updates
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features
NCT06564844
Recruiting
This is a Phase III, randomised, open-label, multicentre, global study assessing the efficacy and safety of adjuvant Dato-DXd in combination with rilvegostomig compared with SoC, after complete surgical resection (R0) in participants with Stage I adenocarcinoma NSCLC who are ctDNA-positive, as determined by the Sponsor-designated ctDNA assay, or have at least one high-risk pathological feature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Research Site, Gilbert, Arizona +220 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
Targeted Therapy With Glycogen Synthase Kinase-3 Inhibition for Arrhythmogenic Cardiomyopathy
NCT06174220
Recruiting
The TaRGET study is a multi-centre, prospective, randomized, double-blind, placebo-controlled trial designed to evaluate the potential therapeutic efficacy of tideglusib, a glycogen synthase kinase-3 β inhibitor, in genotype positive arrhythmogenic cardiomyopathy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Foothills Medical Centre, Calgary, Alberta +16 locations
Conditions: Arrhythmogenic Cardiomyopathy, Arrhythmogenic Right Ventricular Cardiomyopathy
Register for Updates
Evaluation of the Safety and Effectiveness of the CereVasc® eShunt® System in Normal Pressure Hydrocephalus
NCT06498960
Recruiting
Prospective, multi-center, randomized, controlled trial of the eShunt System in the treatment of patients with normal pressure hydrocephalus.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/09/2025
Locations: University of Southern California, Los Angeles, California +25 locations
Conditions: Normal Pressure Hydrocephalus
Register for Updates
PARADIGM: Amplatzer Valvular Plug for PVL Closure
NCT04489823
Recruiting
The Paradigm study is a prospective, multicenter, single arm study to demonstrate the safety and effectiveness of the Amplatzer Valvular Plug III (AVP III) as a treatment for clinically significant PVLs following surgical implant of a mechanical or biological heart valve implanted in the aortic or mitral position.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University Hospital - Univ. of Alabama at Birmingham (UAB), Birmingham, Alabama +28 locations
Conditions: Paravalvular Aortic Regurgitation
Register for Updates
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
NCT04363684
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University of Alabama Birmingham, Birmingham, Alabama +26 locations
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Register for Updates
Evaluating the Effectiveness of the Nurse Ned Clinic
NCT05033301
Recruiting
The purpose of this non-randomized control trial is to evaluate the effectiveness of a virtual nurse-led survivorship clinic for prostate cancer (PCa) survivors. Through this trial, investigators will compare pre-determined survivorship outcomes of men receiving care via traditional specialist-led PCa virtual care model (Specialist Ned) to those receiving care via the newly-proposed nurse-led PCa virtual care model (Nurse Ned). In total, it is anticipated that a maximum of 600 men (300 in contro... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University Health Network (Princess Margaret Hospital), Toronto, Ontario
Conditions: Prostate Cancer
Register for Updates
The INITIATE Study: Initiating Nicotine Dependence Treatment for Smokers Admitted to Emergency Departments
NCT04163081
Recruiting
The INITIATE Study is a randomized controlled trial that is testing an intervention designed to increase long-term abstinence among tobacco smokers seen in emergency departments (ED) and other high-volume hospital and community ambulatory care settings. The intervention includes a behavioural incentive and tailored follow-up support on long-term smoking abstinence, health, healthcare utilization, and cost. Tobacco-related illnesses cost the healthcare system millions each year. Quitting smoking... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University of Ottawa Heart Institute, Ottawa, Ont' +3 locations
Conditions: Nicotine Dependence, Cigarettes, Nicotine Withdrawal
Register for Updates